Skip to content

Study · Non-randomized trial · n = 39 · 2020

7 results

Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials.

Seidner DL, Gabe SM, Lee HM, Olivier C, Jeppesen PB

JPEN. Journal of parenteral and enteral nutrition18 Aug 2019Cited by 30 (Europe PMC)

PMID31423614 (opens in a new tab)PMCIDPMC7318286 (opens in a new tab)DOI10.1002/jpen.1687 (opens in a new tab)PepBankPUB-31423614
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with SBS-IF receiving teduglutide, eight of 39 achieved PS independence during the STEPS series.

    In plain wordsIn adults with SBS-IF receiving teduglutide, eight of 39 became independent of parenteral support.

    Peptide
    Teduglutide
    Outcome
    Not applicablePS independence
    Study

    n = 39

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Patients achieving PS independence
    8 patients
    of 39 teduglutide-treated patients in STEPS

    Source sentences

    Summary
    Eight of 39 patients who received teduglutide in STEPS obtained PS independence during the STEPS study series.
    1 context sentence
    Summary · context
    Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-3 were included in the analysis.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with SBS-IF, enteral autonomy required more than 6 months of teduglutide treatment across disease characteristics.

    In plain wordsIn adults with SBS-IF, independence from parenteral support required more than 6 months of teduglutide treatment.

    Peptide
    Teduglutide
    Outcome
    Not applicableTreatment before enteral autonomy
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated · more than 6 months before enteral autonomy was achievedAs given in this study (human).

    Measurements

    Teduglutide treatment before enteral autonomy
    > 6 months
    patients achieving enteral autonomy

    Source sentences

    Summary
    Patients required > 6 months of teduglutide treatment before enteral autonomy was achieved, regardless of underlying disease characteristics.
    1 context sentence
    Summary · context
    Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-3 were included in the analysis.
  3. 03HumanObservational studyEfficacy outcome

    In teduglutide-treated adults with SBS-IF, patients achieving PS independence tended to have lower baseline PS volumes.

    In plain wordsIn adults receiving teduglutide, support independence was linked to lower baseline support volumes.

    Peptide
    Teduglutide
    Outcome
    DecreaseBaseline PS volume association with independence
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients who attained PS independence and greater numbers of days per week off PS tended to have lower baseline PS volumes and noninflammatory bowel disease (non-IBD) etiology.
    1 context sentence
    Summary · context
    Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-3 were included in the analysis.
  4. 04HumanObservational studyEfficacy outcome

    In teduglutide-treated adults with SBS-IF, patients achieving PS independence tended to have non-IBD etiology.

    In plain wordsIn adults receiving teduglutide, support independence was linked to non-IBD causes of SBS-IF.

    Peptide
    Teduglutide
    Outcome
    Not applicableEtiology association with independence
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients who attained PS independence and greater numbers of days per week off PS tended to have lower baseline PS volumes and noninflammatory bowel disease (non-IBD) etiology.
    1 context sentence
    Summary · context
    Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-3 were included in the analysis.
  5. 05HumanObservational studyEfficacy outcome

    In teduglutide-treated adults with SBS-IF, more days off PS tended to accompany lower baseline PS volumes.

    In plain wordsIn adults receiving teduglutide, more days without support tended to accompany lower baseline support volumes.

    Peptide
    Teduglutide
    Outcome
    DecreaseBaseline volume association with days off PS
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients who attained PS independence and greater numbers of days per week off PS tended to have lower baseline PS volumes and noninflammatory bowel disease (non-IBD) etiology.
    1 context sentence
    Summary · context
    Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-3 were included in the analysis.
  6. 06HumanObservational studyEfficacy outcome

    In teduglutide-treated adults with SBS-IF, more days off PS tended to accompany non-IBD etiology.

    In plain wordsIn adults receiving teduglutide, more days without support were linked to non-IBD causes.

    Peptide
    Teduglutide
    Outcome
    Not applicableEtiology association with days off PS
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients who attained PS independence and greater numbers of days per week off PS tended to have lower baseline PS volumes and noninflammatory bowel disease (non-IBD) etiology.
    1 context sentence
    Summary · context
    Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-3 were included in the analysis.
  7. 07HumanObservational studyEfficacy outcome

    In teduglutide-treated adults with SBS-IF, at least 50% colon-in-continuity showed a trend toward more days off PS.

    In plain wordsIn adults receiving teduglutide, at least 50% colon-in-continuity showed a trend toward more days without support.

    Peptide
    Teduglutide
    Outcome
    IncreaseColon continuity association with days off PS
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Patients with ≥ 50% colon-in-continuity showed a trend for achieving greater numbers of days per week off PS.
    1 context sentence
    Summary · context
    Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-3 were included in the analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.